Company Profile

Advanced Analytical Technologies Inc (AKA: AATI)
Profile last edited on: 10/19/2018      CAGE: 1XRG7      UEI:

Business Identifier: High-throughput nucleic acid analysis systems
Year Founded
1998
First Award
2002
Latest Award
2002
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2450 SE Oak Tree Court 101
Ankeny, IA 50021
   (515) 964-8500
   info@aati-us.com
   www.aati-us.com
Location: Single
Congr. District: 03
County: Polk

Public Profile

In March 2018 it was announced that Agilent Technologies Inc (NYSE:A) had acquired Advanced Analytical Technologies, Inc. (AATI) in an all cash transaction. Until now a privately-held corporation, AATI has developed a rapid microbiology platform to replace the traditional method of growing microbial organisms on agar plates: capillary electrophoresis-based (CE) solutions for fully-automated analysis of a range of molecules. Electrophoresis is a commonly used separation technique to analyze biomolecules such as nucleic acids (RNA and DNA), proteins, carbohydrates and small molecules. With a broad range of applications, the approach is used across a variety of industries, including pharma and biopharma, clinical and diagnostics, food, environmental and forensics, and chemical and energy. Enhancing Agilent's expertise and technology, AATI has developed compelling CE technologies that provide key advances in sensitivity and resolution to address a wide range of applications. AATI solutions are comprised of instruments, software and consumables aimed at simplifying complex workflows. Technology advances in genomics, metabolomics, and proteomics are driving growth and demand for innovative new solutions; for example, AATI has developed optimized screening protocols and QC analysis solutions for CRISPR, an innovative gene-editing technology experiencing rapid growth in development and application.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
100-149
Revenue Range
10M-15M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 1 USDA $80,000
Project Title: Rapid Detection of E.coli O157:H7, Salmonella spp. and Listeria spp.

Key People / Management

  Kurt F Heiar -- former President

  Steven J Lasky -- Founder and Chief Executive Officer

  Kristi R Harkins

  Brian Thompson -- Founder

  Pierre Varineau -- Founder